RDTCF (Rapid Dose Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RDTCF Rapid Dose Therapeutics Corp RDTCF
29 GF Score
Price $0.08
GF Value $0.22
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics Tariff Resilience Score?

Rapid Dose Therapeutics RDTCF 29 Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus rates RDTCF with a GF Score™ of 29/100 and a GF Value™ of $0.22 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Rapid Dose Therapeutics ranks better than 62.41% on this metric.

Rapid Dose Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Rapid Dose Therapeutics has Rapid Dose Therapeutics relies on international markets for both supply and sales, exposing it to tariff risks. While its innovative drug delivery systems offer some pricing power, supply chain disruptions could impact costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Rapid Dose Therapeutics might have Average Resilient.

Rapid Dose Therapeutics  (OTCPK:RDTCF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Rapid Dose Therapeutics Tariff Resilience Score Related Terms

RDTCF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Rapid Dose Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Tariff Resilience Score falls into.


RDTCF
29GF Score
Rapid Dose Therapeutics Corp RDTCF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Rapid Dose Therapeutics (RDTCF) has a Tariff Resilience Score of 5 as of Jul. 14, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Rapid Dose Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Rapid Dose Therapeutics' Tariff Resilience Score too high?
Rapid Dose Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Rapid Dose Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Rapid Dose Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rapid Dose Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Rapid Dose Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Rapid Dose Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Dose Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.22, compared to a current price of $0.08 — trading 64.3% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Rapid Dose Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Tariff Resilience Score is 5 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 64.3% below its estimated GF Value™ of $0.22. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • Tariff Resilience Score: 5
  • GF Value™: $0.22 vs. price of $0.08 (64.3% below fair value)
  • GF Score™: 29/100 with 3 warning signs
  • Industry Position: 25% above the Biotechnology median (#515 of 1370)

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
29GF Score

Get the complete analysis for RDTCF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.22
GF Value